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Abstract: Treatment of HIV-1 infection has produced dramatic success for many patients. 
Nevertheless, viral resistance continues to limit the efﬁ  cacy of currently available agents in 
many patients. The CCR5 antagonists are a new class of antiretroviral agents that target a 
necessary coreceptor for viral entry of many strains of HIV-1. Recently, the ﬁ  rst agent within 
this class, maraviroc, was approved by a number of regulatory agencies, including the Food 
and Drug Administration. Herein we review the role of the CCR5 receptor in HIV-1 infection 
and potential methods to target it in anti-HIV-1 therapy. We review the various categories of 
agents and discuss speciﬁ  c agents that have progressed to clinical study. We discuss in detail 
the recently approved, ﬁ  rst in class CCR5 antagonist, maraviroc, and discuss aspects of resis-
tance to CCR5 antagonism and the potential role of CCR5 antagonism in the management of 
HIV-1 infection.
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Introduction
The widespread use of highly active antiretroviral therapy (HAART) has profoundly 
affected the treatment and epidemiology of HIV-1 infection within the developed world, 
where HIV-1 infection has largely become a chronic illness (Palella et al 1998). HAART’s 
dramatic success has contributed in saving at least 3 million years of life in the US since 
1989 and will aid a patient living with HIV-1 to live more than 13 years longer today than 
if they had been diagnosed in 1988 (Walensky et al 2006). Despite tremendous impact, 
patient beneﬁ  t from HAART is not simple or uniform; 25% of patients starting HAART 
either do not achieve viral suppression or lose it within 2 to 3 years, frequently due to 
viral resistance (Bartlett et al 2001; Mocroft et al 2002; Holmberg et al 2003). Moreover, 
the rate of acquired resistance in patients recently infected with HIV-1 has grown from 
13.2% during the period 1995 to 1998 to 24.1% during 2003 to 2004, including some 
with rapid progression to AIDS (Markowitz et al 2005; Shet et al 2006).
In spite of the recalcitrant nature of HIV-1 viral resistance, recent advances have been 
substantial. The approval of darunavir, a protease inhibitor with potent efﬁ  cacy against 
multi-drug resistant strains of HIV-1, has helped shift the emphasis of HIV-1 salvage 
treatment from preserving immune function to complete suppression of viral replication 
and immune reconstitution (Hammer et al 2006). With the advent of additional classes 
of agents such as CCR5 and integrase antagonists, patients with extensive multi-drug 
resistance will likely be able to achieve an undetectable viral load. Nevertheless, resistance 
to these new agents has already been seen in vitro and will inevitably arise clinically 
(Mosley et al 2006; Cooper et al 2007; Steigbigel et al 2007). HIV clinical investigators 
must be prepared to overcome these defenses by reﬁ  ning the current use of HAART and 
wisely integrating new agents, such as CCR5 antagonists, in order to minimize the impact 
of HIV-1 viral resistance on patients and populations (Schooley and Mellors 2007).Therapeutics and Clinical Risk Management 2008:4(2) 474
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Herein we review the role of the CCR5 receptor in 
HIV-1 infection and potential methods to target it in anti-
HIV-1 therapy. We review the various categories of agents 
and discuss speciﬁ  c agents that have progressed to clini-
cal study. In particular, we discuss in detail the recently 
approved, ﬁ  rst in class CCR5 antagonist, maraviroc, and 
discuss aspects of resistance to CCR5 antagonism and the 
potential role of CCR5 antagonism in the management of 
HIV-1 infection.
Viral entry and CCR5
The mechanism by which HIV-1 infects cells was a prime 
target for early HIV-1 researchers. In 1984, the CD4 molecule 
was identiﬁ  ed as necessary for HIV-1 replication within host 
cells (Dalgleish et al 1984). Later studies showed that CD4 
alone was not sufﬁ  cient for HIV-1 infection of a host cell and 
2 years later, the chemokine receptor CCR5 was identiﬁ  ed 
as a major co-receptor (Dragic et al 1996).
The proteins required for HIV-1 entry into the cell are 
encoded by the env gene, the product of which is the precursor 
to both the gp120 and gp41 glycoproteins (Chan et al 1997). 
Gp120 associates with the CD4 receptor on the surface of the 
host cell; gp41 spans the viral envelope and mediates viral 
fusion with the host cell. The two glycoproteins associate 
non-covalently on the viral envelope as a heterodimer and 
then further assemble as a trimer to form the fusion mediating 
structure (Kwong et al 1998).
On exposure of the virus to a cell expressing CD4, 
gp120 interacts with the CD4 molecule, thereby inducing 
a conformational change in gp120 that enables binding to 
the chemokine receptor (see Figure 1). Binding of gp120 to 
the chemokine receptor (either CCR5 or CXCR4) generates 
a conformational change in gp41, leading to insertion of a 
lipophilic region of gp41, known as the fusion peptide, into 
the lipid bilayer of the host cell. A transitional intermediate 
state is created in which gp41 is inserted into both the viral 
envelope and the cellular membrane. The virus and the cell 
are brought together as gp41 folds on itself in a hairpin 
structure, thereby bringing the viral envelope into close 
proximity with the cell membrane of the CD4+ host cell. 
Fusion is initiated, and the viral core contents are spilled into 
the cytoplasm (Chan et al 1998; Eckert et al 2001).
Figure 1 HIV-1 entry via CD4 and coreceptor binding gp120 binds to CD4 (A) and undergoes conformational changes that expose the co-receptor binding site (B) and enable 
binding to the chemokine receptor (C). Structural changes are then induced in gp41 that extend the helical domains to form a ‘pre-hairpin intermediate’ (D). The hydrophobic 
fusion peptide inserts into the target cell membrane, causing gp41 to span between the virus and cell membranes. The gp41 helices then fold into a six-helix bundle, bringing 
together the N-terminal and C-terminal domains and thus the viral and cellular membranes (E). Contact between the membranes allows mixing of the outer leaﬂ  ets followed 
by the development of a fusion pore (G). gp120 is omitted from panels F and G for the sake of clarity. Reprinted with permission from Starr-Spires LD, Collman RG. 2002. 
HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med, 22:681–701. Copright 2002 © Elsevier.Therapeutics and Clinical Risk Management 2008:4(2) 475
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Structure, location, and function of CCR5
Similar to other G-protein coupled receptors, chemo-
kine receptors have a seven transmembrane structure. 
The N-terminus is extracellular and participates in bind-
ing of the chemokine; the C-terminus is intracellular and 
serves as the site for β-arrestin binding. β-arrestins facilitate 
G-protein independent cell signaling in addition to bind-
ing the chemokine receptor to clathrin for endocytosis 
and subsequent recycling (Zhao et al 1998; Oppermann 
2004; Signoret et al 2005). Two separate co-receptors for 
HIV-1 infection have been identiﬁ  ed: CCR5 and CXCR4. 
There is substantial genetic variability within the amino 
acid sequence of gp120 molecule on the viral envelope, 
determining to which chemokine receptor the gp120 will 
bind (Pastore et al 2006).
The ligands for CCR5 and CXCR4 are chemokines, which 
are small molecules in the cytokine family that promote che-
motaxis and cellular activation; on binding to their receptor 
on the target cell, an intracellular signaling cascade is initiated 
via a G-protein release from the intracellular domain of the 
receptor (Oppermann 2004). Native ligands for CCR5 include 
chemokines MIP-1α (macrophage inﬂ  ammatory protein), 
MIP-1β, and RANTES (regulated on activation, normal T-cell 
expressed and secreted), which have been giving standard 
nomenclature CCL3, CCL4, and CCL5, respectively; CCR5 is 
expressed on immune cells, including effector and memory 
T-cells, natural killer cells, and antigen presenting cells 
(Blanpain et al 1999; Rufﬁ  ng et al 1998). As is exempliﬁ  ed 
by CCR5 and its ligands, the host defense mechanism is both 
complex and redundant. A single chemokine receptor can 
be activated by different chemokines, and similarly, a single 
chemokine may also activate multiple different chemokine 
receptors. This redundancy provides a back up plan to coun-
teract the strategies and mutations microbes use to circumvent 
the host defense system.
CCR5 is heavily involved in both initiating and amplifying 
the immune response. At the time of microbial invasion, 
conserved antigens on the microbe bind to toll-like receptors 
on the surface of macrophages and immature dendritic cells, 
which release cytokines and chemokines in response. CCR5 
expressing cells are then drawn toward the site of invasion by the 
high concentration of CCR5 binding chemokines; they ingest 
Figure 2 Development of maraviroc from the high-throughput screening hit UK-107,543. Reprinted with permission from Dorr P, Westby M, Dobbs S, et al 2005. Maraviroc 
(UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeﬁ  ciency virus type 1 
activity. Antimicrob Agents Chemother, 49:4721-32. Copyright © American Society of Microbiology.Therapeutics and Clinical Risk Management 2008:4(2) 476
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pathogens, mature, and then migrate to lymphoid tissue where 
they then prime the adaptive immune response by presenting 
the microbial antigens to naive B- and T-lymphocytes (Wong 
et al 2003). Antigen-speciﬁ  c T-lymphocytes can also release 
CCR5-binding chemokines, which bind to endothelial cells 
and components of the extracellular matrix. CCR5 expressing 
cells roll along the surface of the endothelium and are drawn 
to the increased chemokine gradient at the site of infection 
(Wong et al 2003, Luther et al 2001). Of note, while CCR5 
has several identiﬁ  ed agonists, CXCR4 has only one (Stromal 
derived factor-1).
Distribution of CCR5-tropic virus 
in the HIV-positive
HIV-1 is capable of using either CCR5 or CXCR4 as a 
co-receptor in vivo; in vitro, it has been shown to use other 
chemokine receptors (Unutmaz et al 1998). Some strains of 
HIV-1, known as R5, use only CCR5 as the co-receptor to 
gain access to the host cell. Other strains, X4 strains, use only 
CXCR4 as its co-receptor. Dual or mixed (D/M) strains, also 
known as R5X4 strains, can use both CCR5 and CXCR4.
In early infection, the vast majority (70%–80%) of strains 
isolated from treatment-naïve patients are CCR5-tropic or R5 
viruses (Brumme et al 2005; Moyle et al 2005), whereas X4 
strains, previously known as syncytium-inducing variants, 
are seen in 30%–60% of treatment-experienced patients and 
arise later in the natural history of HIV-1 infection. They 
are associated with accelerated progression to AIDS and 
lymphocyte depletion. It is unclear whether the appearance 
of variants that use CXCR4 as a co-receptor is a cause or 
an effect of immunodeﬁ  ciency (Koot et al 1993; Connor 
et al 1997; Melby et al 2006; Wilkin et al 2007). It should 
be noted that R5 strains still persist late into the course of 
disease, so the CCR5 co-receptor may still be an important 
pharmaceutical target even in advanced stages of disease 
(Wilkin et al 2007).
Natural variant of CCR5
In 1996, a 32 base pair mutation in the gene for CCR5, 
known as ∆32, was shown to protect against HIV-1 infection 
(Huang et al 1996). The mutant allele codes for a dysfunc-
tional truncated protein that is not expressed on the surface 
of the cell. The frequency of the allele is approximately 
10%–14% in the white population, particularly those of 
Northern European descent, but is seldom seen in Asians or 
Africans; approximately 1% of the Caucasian population is 
homozygous for the deletion (Liu et al 1996). Infection of 
∆32 homozygotes is exceedingly rare, and when it occurs 
is caused by viruses using CXCR4 as a co-receptor for viral 
entry; heterozygotes can be infected with the HIV-1 virus 
but tend to have a longer disease course (Dean et al 1996; 
Liu et al 1996; Samson et al 1996). Patients who are homo-
zygous for the ∆32 mutation are phenotypically normal, 
without readily apparent negative effects or decreased life 
expectancy. The preserved functional phenotype of ∆32 
homozygotes is attributable to the redundancy present in 
the host defense system. Interestingly, mutations in murine 
CXCR4 (or its only known native ligand, Stromal factor-1) 
are lethal in the embryo (Lapidot 2001).
However, recent evidence suggests ∆32 homozygotes 
may have immunological consequences. Early research-
ers proposed that the mutation, in its early age, may have 
provided protection against Yersinia pestis (Stephens et al 
1998), the microbial agent of the bubonic plague; others 
have suggested that protection against smallpox may have 
been the survival advantage (Galvani et al 2003). The area 
remains controversial, and recent population studies indicate 
that evolution of CCR5 may have been neutral (Sabeti et al 
2005). Another study demonstrated longer survival and 
delayed rejection of renal allografts in ∆32 homozygotes 
(Fischereder et al 2001), and CCR5∆32 may be protective 
against the development of rheumatoid arthritis and persistent 
hepatitis B infection (Prahalad et al 2006; Thio et al 2007). 
The ∆32 mutation has also been associated with increased 
mortality from encephalopathy caused by West Nile Virus 
(Glass et al 2006). Additional studies will likely reveal other 
previously unrecognized complications or beneﬁ  ts associated 
with absence, dysfunction, or blockade of CCR5.
Targeting CCR5
A number of potential mechanisms are under investigation 
to inhibit HIV-1 binding and fusion to human cells. These 
include agents to block CD4 binding by viral gp120, inhibit 
CCR5 or CXCR4 co-receptor binding by gp120, as well 
as inhibit gp41 mediated fusion of the viral and cellular 
lipid bilayers as the Food and Drug Administration (FDA)-
approved agent enfuvirtide does (Guo et al 2003; Jacobson 
et al 2004; Oldﬁ  eld et al 2005; Kadow et al 2006; Moyle 
et al 2007). While it is beyond the scope of this review 
to discuss every agent, we will review developmentally 
advanced agents and the various tactics under study for the 
antagonism of CCR5.
With the initial discovery that CCR5 was an HIV-1 co-
receptor and its endogenous ligands, (MIP-1α, MIP-1β, 
and RANTES) able to suppress HIV-1 replication, efforts 
centered on pharmacologically reproducing the effects of Therapeutics and Clinical Risk Management 2008:4(2) 477
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these chemokines. This antiviral effect is related to the 
ligands’ ability to internalize the receptor and deprive it 
from being expressed on the cell surface (Cocchi et al 1995). 
The promise of these modiﬁ  ed chemokines and other novel 
agents has been difﬁ  cult to bring to fruition thus far and their 
future remains uncertain (Simmons et al 1997; Qin et al 2003; 
Hartley et al 2004; Anderson and Akkina 2007). Another 
unique approach attempts to employ a zinc ﬁ  nger nuclease 
to bind, cleave, and cause mutagenesis in the CCR5 gene and 
thereby inhibit normal transcription and protein expression 
(Jouvenot et al 2005; Mani et al 2005).
Monoclonal antibodies targeting CCR5 have also been 
developed with CCR5mAb004 of Human Genome Sci-
ences (Rockville, MD, USA), and PRO 140 of Progenics 
Pharmaceuticals (Tarrytown, NY, USA) progressing to early 
phase human trials. Each is a mouse-derived but humanized 
monoclonal antibody capable of blocking CCR5 without 
activation of the receptor (Olson et al 1999; Roschke et al 
2004). A phase I study in 63 HIV-positive patients with 
CCR5-tropic virus demonstrated CCR5mAb004 to be safe 
and well tolerated with substantial anti-viral efﬁ  cacy for up 
to 28 days after a single dose (Lalezari et al 2006). Subjects 
were randomized to 5 cohorts with an 8:2 ratio of placebo 
to active drug. Subjects were infused with a single dose of 
placebo or CCR5mAb004 at 1 of 5 dosages, 0.4, 2, 8, 20, or 
40 mg/kg of body weight, and followed for 8 weeks. Greater 
antiviral response was observed at higher doses with 55% of 
subjects receiving doses of 8 mg/kg or greater and 50% in the 
highest dose cohort demonstrating at least a 1 log10 drop in 
HIV viral load. Further investigation of a more potent, next 
generation antibody is anticipated.
PRO 140, considered a fast-track product by the FDA, 
recently reported positive proof-of-concept study results. 
A phase I study in 39 HIV-positive patients with CCR5-tropic 
virus demonstrated PRO 140 to be safe, well tolerated and a 
potent inhibitor of HIV-1 replication with a mean maximal 
viral load reduction of 1.83 log10 in the highest dose group 
(5 mg/kg) after a single dose (Jacobson et al 2007). All 
patients receiving the highest dose had a viral load reduction 
of at least 1 log10. PRO140 binds to the N terminus and second 
extracellular domain of CCR5 and acts as a direct competitive 
inhibitor of HIV binding. The small-molecule antagonists to 
be discussed bind in a hydrophobic pocket of CCR5 formed 
by transmembrane helices, and act through allosteric effects. 
As such, the two classes of CCR5 antagonists work through 
different mechanisms, and virus resistant to the small mol-
ecule antagonists maintain sensitivity to PRO140 (Kuhmann 
et al 2004; Marozsan et al 2005). In addition, in vitro 
studies demonstrate potentially synergistic effects with the 
small-molecule CCR5 antagonists (Murga et al 2006; Ji et al 
2007). Though PRO 140 requires parenteral administration, 
the interval of administration ultimately determined could be 
long enough to be reasonably convenient. The preliminary 
results are encouraging.
By far the largest group and furthest in development of 
CCR5 antagonists are the small-molecule inhibitors. Typically 
cheaper to produce than peptides with better oral bioavailability, 
these agents also demonstrate signiﬁ  cant potency across diverse 
clades with half maximal inhibitory concentrations (IC50) 
measured in nanomoles. As is the case with many small-molecule 
inhibitors of G-coupled proteins, these agents appear to bind 
a pocket within the transmembrane helices, alter extracellular 
CCR5 conformation, and thereby inhibit HIV-1 binding (Dragic 
et al 2000). Agents that have progressed from simple labels 
to scientiﬁ  c names end in the sufﬁ  x–viroc, eg, vicriviroc, to 
denote their action of viral receptor occupancy. Small-molecule 
antagonists include: TAK-779, TAK-220, Tak-652, AK602/
ONO4128/GSK-873140/aplaviroc, SCH-C/SCH-351125, 
SCH-D/SCH-417690/vicriviroc, and UK-427,857/maraviroc. 
In addition to the recently approved maraviroc, which we 
discuss in greater detail in the following section, a number of 
other agents merit discussion.
The ﬁ  rst small-molecule CCR5 antagonist published was 
TAK-779 of Takeda Chemical Industries (Osaka, Japan) 
(Baba et al 1999). Though a potent inhibitor of CCR5-tropic 
HIV-1 in vitro, development was curtailed due to the need 
for subcutaneous administration and the attendant difﬁ  cul-
ties with injection site reactions. More recent focus has been 
placed on TAK-220 and TAK-652, each with nanomolar 
inhibition of HIV-1 in vitro and oral bioavailability (Baba 
et al 2005; Takashima et al 2005). A single-dose phase I 
study has been completed for TAK-652 and demonstrates 
favorable initial safety and pharmacokinetic data (Baba et al 
2005). Further clinical data are awaited.
Spirodiketopiperazine derivatives have been under active 
development by Ono Pharmaceuticals (Osaka, Japan) in 
collaboration with GlaxoSmithKline (Research Triangle 
Park, NC, USA). E913 potently suppresses the replication of 
laboratory and primary CCR5-tropic HIV-1 strains, including 
viruses resistant to available antiretroviral medications (Maeda 
et al 2001). However aplaviroc (AK602/ONO4128/GSK-
873140) demonstrates a 2-fold increase in activity versus 
HIV-1 isolates at sub-nanomolar concentration both in vitro 
and in vivo mouse model, and became the lead analogue 
under development (Maeda et al 2004; Nakata et al 2005). In 
early phase study, a maximum dose of 600 mg twice a day for Therapeutics and Clinical Risk Management 2008:4(2) 478
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10 days demonstrated a 1.66 log10 mean reduction in viral load 
and was well tolerated (Lalezari et al 2005). However during 
phase IIb trials three subjects developed severe hepatotoxicity, 
which was deemed secondary to drug-induced hepatitis. 
Moreover, 1 of the ﬁ  rst 44 subjects enrolled in a phase III trial 
of aplaviroc developed severe hepatotoxicity, and the trials and 
development of aplaviroc were stopped (Crabb 2006).
CCR5 antagonist, SCH351125 or SCH-C, was the 
first agent developed by Schering-Plough Corporation 
(Kenilworth, NJ, USA) due to its antiviral potency-- nano-
molar IC50 concentrations for a range of CCR5-tropic HIV-1 
isolates-- and advantageous pharmacokinetic characteristics 
(Strizki et al 2001). The ﬁ  rst CCR5 antagonist to enter 
clinical efﬁ  cacy studies, SCH-C at a dose of 25 mg twice 
daily demonstrated a 0.5–1 log drop in viral load in 10 of 
12 subjects (Reynes et al 2002). However, antiviral effect 
was not uniform and QTc interval prolongation prompted 
further optimization work. This resulted in Sch-417690 or 
SCH-D, later known as vicriviroc. Vicriviroc is 2–40 times 
more potent than SCH-C against primary HIV-1 isolates in 
vitro, has excellent oral bioavailability, and an improved 
safety proﬁ  le (Strizki et al 2005).
In early phase study, vicriviroc was well tolerated up to 
50 mg twice daily and produced 1.5 to 1.6 log reductions in 
HIV-1 viral load at doses of 25 mg and 50 mg twice daily in 
treatment-naïve subjects (Schurmann et al 2007). However, 
treatment-naïve subjects with R5-tropic virus fared less well 
in a phase II study comparing vicriviroc to efavirenz (EFV), 
both combined with zidovudine/lamivudine (AZT/3TC as 
ﬁ  xed dose Combivir® [GlaxoSmithKline]). Subjects began 
the study receiving either placebo or vicriviroc monother-
apy (25, 50, or 75 mg once daily) for 2 weeks. Thereafter 
AZT/3TC was added to subjects receiving vicriviroc, while 
subjects receiving placebo were given EFV and AZT/3TC 
instead. Though vicriviroc produced a 0.9–1.3 log10 greater 
reduction in viral load than placebo, preliminary analysis 
demonstrated virologic breakthrough (RNA   50 copies/mL) 
during follow-up in 2 of 24 (8%) of the placebo/AZT/3TC/
EFV group versus 13 of 23 (57%), 10 of 22 (45%), and 5 
of 23 (22%) in the 25, 50, and 75 mg arms of vicriviroc, 
respectively (Greaves et al 2006). The study was subse-
quently terminated prematurely on recommendation of the 
data safety monitoring board. Neither tropism shifts nor 
elevated vicriviroc IC50 measurements accounted for the 
higher rate of virologic breakthrough. However, all subjects 
with virologic breakthrough and genotypic data available 
had treatment-emergent M184V mutations, suggesting that 
vicriviroc was underdosed. Such results have provoked calls
that there is a near unassailable standard of care in 
treatment-naïve regimens, eg, EFV-based, and that these 
potent regimens should be embraced (Deeks 2006).
Phase II vicriviroc results have been more encourag-
ing among treatment-experienced subjects. In an AIDS 
Clinical Trial Group study, ACTG A5211, 24 week and 
recently presented 48 week data has shown that vicriviroc 
provided a signiﬁ  cant advantage over placebo when added 
to optimized background regimen (Gulick et al 2007a, b). 
Both the 10 mg and the 15 mg once daily doses were shown 
to provide durable virologic suppression and signiﬁ  cant 
immunologic beneﬁ  t: HIV-1 RNA decreases of 1.9 and 
1.4 logs, and CD4+ cell count increases of 96 and 130 cells/
mm3 were seen in the 10 mg and 15 mg arms, respectively. 
Moreover, 37% of subjects in the 10 mg vicriviroc group 
and 27% of those in the 15 mg group had a HIV-1 viral load 
below 50 copies/mL at week 48. However, the 5 mg dose 
study arm was discontinued early based on recommenda-
tion from the Study Monitoring Committee and the study 
was also unblinded following reports of 5 malignancies in 
subjects receiving vicriviroc. Further follow-up of 39 subjects 
enrolled in an open label extension study reported no new 
malignancies and in September 2007, it was announced that 
two phase III studies, entitled VICTOR-E3 and VICTOR-E4, 
had begun to evaluate the safety and effectiveness of 30 mg 
of vicriviroc plus optimized background therapy (OBT) in 
treatment-experienced subjects (Gulick et al 2007c).
Maraviroc
With greater understanding of the role and impact of the 
CCR5 receptor in the transmission and progression of HIV-1 
disease, numerous efforts to pharmacologically target the 
CCR5 receptor began. Drug development work at Pﬁ  zer 
Inc. (Kent, UK) resulted in the development of UK-427,857 
or maraviroc (Dorr et al 2005; Wood and Armour 2005). 
Opening effort centered on a high throughput screening 
assay employing HEK-293 cells to express CCR5 and used 
candidate drug antagonism of radiolabelled MIP-1β binding 
as the basis of the screen resulting in hits UK-107,543 and 
UK-179,645.
Following intensive structure-activity relationship 
(SAR) studies and numerous structural modifications 
via modern medicinal chemistry, UK-427,587, or 
4,4’-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-
(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1] 
oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamid, became 
the lead analogue (see Figure 1). With its ability to block CCR5 
binding and signaling at nanomalor concentrations plus no Therapeutics and Clinical Risk Management 2008:4(2) 479
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problematic cytochrome P450 D2 interaction or cardiac ion 
channel binding, and favorable permeability characteristics, 
further investigation began of this potent inhibitor of laboratory 
optimized HIV-1 isolates (mean inhibitory concentration of 
90% of isolates or IC90 of 2.0 nM).
Additional work demonstrated encouraging pharma-
cokinetic data, and high selectivity for the CCR5 receptor 
compared to other pertinent receptors, eg similar chemokine 
receptors. The antiretroviral activity of UK-427,587 proved 
potent against primary HIV-1 isolates from a number of 
clades, as well as drug-sensitive and drug-resistance clinical 
isolates of HIV-1 both as monotherapy and in concert with 
additional antiretrovirals. UK-427,587’s mechanism of 
action was also conﬁ  rmed to be strictly attributable to CCR5 
blockade and no other antiviral means, eg, cell lysis.
Measurements made in first-in-man studies closely 
matched expectations derived preclinically (Dorr et al 2005; 
Wood and Armour 2005). Single doses were tolerable up 
to 900 mg, multiple doses to 600 mg daily, and twice daily 
doses of 100 mg of maraviroc continuously maintained 
plasma exposure above the IC90. No worrisome laboratory 
or electrocardiographic ﬁ  ndings were observed and phase IIa 
efforts with 10 days of maraviroc monotherapy in the HIV-1 
infected commenced shortly thereafter.
These two studies (A4001007 and A4001015) were 
combined for analysis and reported in November 2005 
(Fätkenheuer et al 2005). Investigators randomized 82 
CCR5-positive subjects to receive 10 days of treatment with 
maraviroc (25 mg, 100 mg or 300 mg once daily or 50 mg, 
100 mg, 150 mg [fed and fasted] or 300 mg twice daily) or 
placebo. Baseline subject characteristics were similar across 
treatment groups and barring one subject inadvertently 
enrolled with D/M infection, subjects receiving 100 mg 
twice daily or more demonstrated robust HIV-1 suppression. 
Maximum viral load reductions averaged –1.68 (range –2.10 
to –1.37) for the 100 mg twice daily group and peaked at 
–1.84 (range –2.42 to –1.49) for 300 mg twice daily. These 
values frequently occurred after day 11 and likely reﬂ  ect the 
prolonged occupancy of the CCR5 receptor by maraviroc, 
a phenomenon also reported for other CCR5 antagonists 
(Lalezari et al 2005; Schurman et al 2007). Three subjects 
were excluded from analysis; the aforementioned subject 
inadvertently enrolled with D/M infection, a subject who with-
drew consent, and a subject who discontinued treatment prior 
to day 3 secondary to a moderate headache felt to be unrelated 
to their 100 mg once daily dose. Maraviroc was generally well 
tolerated, except for one case of severe diarrhea in the 150 mg 
twice daily (fed) group which started on day 1 and resolved 
after 11 days without intervention. The most common mild 
or moderate side effects were headache, asthenia, dizziness, 
gingivitis, and nausea. Overall these results were one of 
the ﬁ  rst to demonstrate the viability of targeting the CCR5 
receptor in the treatment of HIV-1 infection.
Late phase efforts in maraviroc’s development have 
targeted both treatment-naïve and treatment-experienced 
patients. Among treatment-naïve patients, maraviroc is 
being investigated in the MERIT study. This ongoing phase 
IIb/III study had interim 48-week data presented at the 
4th IAS Conference on HIV Pathogenesis, Treatment and 
Prevention held July, 2007 (Saag et al 2007). This study tests 
the hypothesis that maraviroc is not inferior to EFV when 
used in combination with AZT/3TC (provided as ﬁ  xed dose 
Combivir) in CCR5-tropic patients without resistance to 
AZT, 3TC or EFV. Subjects were stratiﬁ  ed at entry by HIV-1 
viral load (  or  100,000 copies/mL) and also geographic 
location (Northern vs Southern Hemisphere). Of note, in 
an effort to minimize discontinuance due to medication 
intolerance, especially AZT, subjects who experienced 
toxicity were allowed to substitute an alternative nucleoside 
reverse transcriptase inhibitor. The primary endpoint was 
the proportion of patients who achieved a viral load  50 
copies/mL through 48 weeks, which proved important to the 
investigators’ conclusions.
Initially planned with three treatment groups, maraviroc 
300 mg once or twice daily or EFV, the data safety and 
monitoring board closed the once-daily maraviroc arm early 
because of inadequate response rates. The remaining study 
arms recruited 721 subjects with a mean age of 37 years, 
79% men/21% women, roughly 50% white/35% black, and 
roughly 400 from the Northern Hemisphere vs 300 from the 
Southern Hemisphere. At baseline, subject characteristics 
were similar between the EFV and maraviroc groups: median 
CD4 counts of 241 and 254 cells/mm3, respectively, and mean 
viral load of roughly 4.9 log copies/mL each.
By 48 weeks, 65.3% of the maraviroc arm and 69.3% of the 
EFV arm achieved a viral load  50 copies/mL. This margin 
of difference failed to meet the preselected criteria for nonin-
feriority as the lower bound of the 97.5% conﬁ  dence interval 
was less than –10% (observed noninferiority margin –10.9%). 
Using an endpoint of  400 copies/mL at 48 weeks, twice daily 
maraviroc met noninferiority criteria as 70.6% of subjects in 
the maraviroc arm and 73.1% of the EFV arm achieved the 
endpoint. Also by 48 weeks, a greater increase in mean CD4 
cell count was observed in the maraviroc treated subjects than 
in the EFV treated (170 cells/mm3 vs 144 cells/mm3) though 
this difference likely has little clinical relevance.Therapeutics and Clinical Risk Management 2008:4(2) 480
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Two subgroup analyses are of particular note. Among 
subjects with baseline viral loads  100,000 copies/mL 
EFV and maraviroc had similar rates of suppression to  50 
copies/mL (71.6% vs 69.6% respectively). However, EFV was 
superior to maraviroc when baseline viral load was  100,000 
copies (proportion with viral loads  50 copies/mL, 66.6% 
vs 59.6%). The two geographic regions also demonstrated 
a difference in response. Higher rates of response were 
observed with EFV in subjects from the Southern hemisphere 
(proportion with viral loads  50 copies/mL, 71.0% vs 62.1%) 
while similar rates of response were observed in subjects 
from the Northern Hemisphere. No underlying mechanism(s) 
has been clearly identiﬁ  ed for this difference though clade 
variation between hemispheres may play a role.
Rates of study drug discontinuation were similar in the 
two groups (26.9% for maraviroc and 25.2% for EFV) though 
reasons did differ. Subjects receiving EFV were more likely 
to stop due to adverse events (13.6% vs 4.2%; typically 
neuropsychiatric side effects such as abnormal dreams and 
dizziness) while subjects receiving maraviroc experienced 
higher rates of virologic failure (11.9% vs 4.2% in the EFV 
arm). Subjects taking maraviroc had fairly more frequent 
cases of bronchitis, and nose and throat infections.
Further safety analyses demonstrated similar proportions 
of severe adverse events as well as severe (grade 3 or 4) liver 
enzyme disturbances, which were infrequent in both groups 
but nevertheless helped prompt an FDA “black box” warning 
regarding potential hepatotoxicity. Rates of new malignan-
cies also did not differ between the treatment groups, which 
is a reassuring ﬁ  nding after initial concerns regard increased 
risk of malignancy with vicriviroc and potentially all CCR5 
antagonists. Overall, maraviroc performed very well in the 
MERIT study but fell just short of rivaling EFV, an agent 
considered by some to be a standard worth embracing (Deeks 
2006).
Two identical studies, MOTIVATE 1 and MOTIVATE 2, 
are investigating maraviroc in treatment-experienced 
CCR5-tropic HIV-1 positive patients (Lalezari et al 2007; 
Nelson et al 2007). Identical in design, these phase IIb/III 
studies included subjects with: resistance to and/or  6 months 
experience with at least one antiretroviral agent from each 
of the three approved oral drug classes (at least 2 agents for 
protease inhibitors), HIV-1 viral load of  5,000 copies/mL 
and either off treatment or on a stable but failing antiretroviral 
regimen for at least four weeks. Subjects were stratiﬁ  ed by 
enfurvitide use as well as viral load   or  100,000 copies/mL. 
Applying genotypic and phenotypic test results, subjects were 
randomized to receive OBT plus placebo, maraviroc once daily 
or maraviroc twice daily (subjects receiving a PI other than 
tipranavir and/or delavirdine in their OBT received 150 mg 
while remaining subjects received 300 mg) in a 1:2:2 ratio.
Interim results from planned 24-week analyses of both 
trials were very similar (see Table 1). MOTIVATE 1 enrolled 
601 subjects mainly from North America, while MOTIVATE 2 
enrolled 475 individuals mainly from Europe and Austra-
lia. In each study the vast majority of subjects were male 
(84%–91%) and predominately white (81%–87%). Baseline 
characteristics were similar across treatment groups in both 
studies. Median baseline CD4+ cell counts ranged from 150 
to 182 cells/mm3, median baseline viral loads from 4.84 to 
4.89 log10 copies/mL, enfuvirtide (T-20, Fuzeon) use from 
37% to 46% of subjects, and the majority of subjects had 2 or 
fewer active agents in their OBT (66%–76% and 62%–66% 
in MOTIVATE 1 and 2, respectively).
Maraviroc arms in both studies demonstrated highly 
statistically signiﬁ  cant virologic and immunologic beneﬁ  ts 
compared with the placebo groups. Maraviroc was very well 
tolerated, with no differences observed in the rate of study 
discontinuation or grade 3/4 adverse events across treat-
ment arms. Importantly, no excess of cancer diagnoses or 
liver function abnormalities were observed in the maraviroc 
groups compared to placebo.
Combined analysis of the two studies was performed 
to assess maraviroc’s contribution to viral suppression. As 
Table 1 24-week results of phase III maraviroc studies in CCR5-tropic subjects (Lalezari et al 2007; Nelson et al 2007)
24 week outcome MOTIVATE 1 and MOTIVATE 2 Results respectively
Placebo + OBT MVC once daily + OBT MVC twice daily + OBT
Mean change in HIV-1 viral load from
baseline (log10 copies/mL)
–1.03, –0.93 –1.82, –1.95 –1.95, –1.97
HIV-1 viral load  400 copies/mL (%) 31.4, 23.1 54.7*, 55.5* 60.4*, 61.3*
HIV-1 viral load  50 copies/mL (%) 24.6, 20.9 42.2*, 40.8* 48.5, 45.6*
Mean change in CD4+ cell count
from baseline (cells/mm3)
+52, +64 +107*, +112* +111*, +102*
*p   0.001 in comparison with placebo.
Abbreviations: MVC, maraviroc; OBT, optimized background therapy.Therapeutics and Clinical Risk Management 2008:4(2) 481
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expected, with an increasing number of active agents in the 
OBT, the greater the likelihood of reaching an undetectable 
viral load. Subjects in the maraviroc arms achieved a much 
higher proportion of complete viral suppression when two or 
fewer active agents were present in the OBT in comparison 
with the placebo arm. This is consistent with numerous prior 
studies demonstrating that two active agents are keys to a 
successful salvage regimen.
More recent combined 24-week analyses demonstrated 
results similar to the individual studies (see Table 2; Gulick 
et al 2007d). While the studies were not designed for a 
formal comparison of once daily and twice daily maraviroc 
dosing, higher rates of virologic suppression were observed 
with twice-daily maraviroc than with once-daily maraviroc 
in several important subgroups: subjects with viral loads 
 100,000 copies/mL at screening, and also subjects with 
baseline CD4 counts  50 cells/mm3. With such robust data, 
the makers of maraviroc requested and received accelerated 
approval by the FDA for treatment-experienced patients 
with inadequate control of multidrug resistant, CCR5-tropic 
HIV-1. In conjunction with maraviroc’s approval, the single-
cycle recombinant virus tropism assay (Troﬁ  le®, Monogram 
Biosciences South San Francisco, CA, USA) also began its 
commercial availability (Coakley et al 2005).
While the approval of maraviroc is for the treatment of 
patients with CCR5-tropic virus, its potential in patients 
with D/M-tropic virus has also been evaluated. Pﬁ  zer study 
A4001029 is a double-blind placebo controlled study in sub-
jects with D/M-tropic virus who were randomized to OBT 
including at least one sensitive drug, plus either maraviroc 
once daily, maraviroc twice daily, or placebo (Goodrich 
et al 2007). 186 subjects with D/M virus and advanced 
immunodeﬁ  ciency, approximate median CD4 cell count of 
42 cells/mm3 and HIV viral load of 5.1 log copies/mL within 
each cohort, were enrolled across the study.
After 48 weeks, the mean viral load decreases were 0.62 
log copies/mL in the once-daily maraviroc group, 1.11 log 
copies/mL in the twice-daily group, and 0.84 log copies/mL 
in the placebo group. These differences were not statistically 
signiﬁ  cant and there was also no substantial difference across 
study cohorts in the proportion of subjects who achieved an 
undetectable viral load. However, despite a lack of antiretroviral 
beneﬁ  t, CD4 cell counts did rise in both maraviroc cohorts, by 
65 cells/mm3 in the once daily arm and 78 cells/mm3 in the 
twice daily arm, whereas the placebo cohort CD4 cell count 
increase was only 51 cells/mm3. This ﬁ  nding has generated 
interest in the possibility that maraviroc, or CCR5 antagonists 
in general, may have an effect on elevating CD4 cell counts 
independent of antiviral activity.
Similar rates of adverse effects and deaths were observed, 
while no cases of lymphoma or adenocarcinoma occurred. 
Thus, in addition to further reassurance of maraviroc’s safety 
proﬁ  le, the lack of HIV progression in the D/M group was 
quite signiﬁ  cant and deserves additional investigation as 
concerns linger regarding the impact of X4-tropic virus.
Consequences of CCR5 antagonist 
treatment
A number of concerns, some unique and others general, are 
germane to the potential use of CCR5 antagonists in patients. 
As previously discussed, targeting CCR5 leaves a patient 
without the role of the CCR5 receptor in innate immunity. 
However, the natural example of the ∆32 CCR5 allele and the 
redundancy of chemokine receptor function provide signiﬁ  -
cant reassurance that blockade should be tolerable. Whether 
untoward consequences of the iatrogenic loss of the CCR5 
receptor’s function, including an undue number of severe 
West Nile virus infections in WNV endemic areas, is a central 
question that will prove important to CCR5 antagonist use.
Also, just as with all antiretrovirals to date, the issue of 
viral escape has attended the development of CCR5 antago-
nists. This concern takes on more substance with CCR5 
antagonists than other agents as failure of HAART using 
a CCR5 antagonist may result in co-receptor switching to 
Table 2 Contribution of maraviroc at 24 weeks to viral suppression based on overall susceptibility score of phase III maraviroc studies 
(Gulick et al 2007d)
Combined analyses of MOTIVATE 1 and MOTIVATE 2 results at 24 weeks
Number of active agents 
in OBT based on overall 
susceptibility score
HIV-1 viral load  50 copies/mL (%)
Placebo + OBT MVC once daily + OBT MVC twice daily + OBT
0 3 18 29
1 9 43 43
21 9 5 2 5 3
 3 55 61 58
Abbreviations: MVC, maraviroc; OBT, optimized background therapy.Therapeutics and Clinical Risk Management 2008:4(2) 482
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CXCR4. Whether de novo or through promotion of minor 
D/M or CXCR4 using variants already present within the 
patient, co-receptor switching would be a troubling outcome 
as D/M and CXCR4 tropic viruses have historically, but not 
uniformly, been associated with accelerated CD4 cell loss and 
progression to AIDS (Philpott 2003; Daar et al 2007; Goetz 
et al 2007). Nevertheless it remains possible that emergence 
of CXCR4 using virus is a consequence and not a cause of 
severe immunodeﬁ  ciency.
Some data addressing co-receptor switching in the set-
ting of CCR5 antagonist use have been reported. Analysis 
of co-receptor switching during early studies of maraviroc 
suggests that emergent D/M and CXCR4 tropic viruses result 
from a pre-treatment reservoir not detected by screening 
tropism assays (Westby et al 2006). During MOTIVATE 1 
and 2, maraviroc’s phase III trials, 63 of 751 MVC treated 
subjects failed with D/M or X4-tropic virus compared to 35 
R5-tropic subjects failing with R5-tropic virus. Reassuringly, 
patients failing a maraviroc regimen with D/M or X4-tropic 
virus had higher mean increases in CD4 count vs placebo 
at time of failure (range +37 to +56 cells/µl vs +14 cells/µl 
respectively). Approximately two thirds of these subjects had 
their D/M or X4 virus return to R5 tropism prior to going 
off study (median = 203 days), and there was no association 
between CXCR4-using virus and AIDS-deﬁ  ning events. Time 
to failure with a D/M or X4-tropic virus was also shorter than 
for failure with a CCR5-tropic virus. Overall, these results are 
consistent with the selective and reversible suppression of R5 
virus during maraviroc therapy (van der Ryst et al 2007).
In vitro studies have also demonstrated that viral escape 
may be a consequence of viral adaptation to the conforma-
tional change in CCR5 caused by CCR5 antagonist binding. 
Laboratory isolates of HIV-1 have demonstrated the ability 
to generate mutations in the V3 region of gp120 that allow 
cell entry via vicriviroc- or maraviroc-bound CCR5 (Pugach 
et al 2007; Westby et al 2007). Emerging data demonstrate 
multiple pathways and signiﬁ  cant complexity to CCR5 
resistance. Preliminarily it appears these mutations are not 
as stereotypical as those for other antiretroviral agents but 
rather speciﬁ  c to the env background of the individual virus 
(Mori et al 2007; Tsibris et al 2007).
Role in HIV-1 therapy 
and conclusions
Evidenced by the FDA and European Medicines Agency’s 
(EMEA) recent approval of maraviroc (as Selzentry® in the 
USA and Celsentri® in the EU), CCR5 antagonists are a wel-
come addition to the care of treatment-experienced patients 
with CCR5-tropic virus. Their potential role in treatment-naïve 
patients is unsupported at this time, considering the shortfalls 
of both maraviroc and vicriviroc based regimens against an 
EFV based regimen. This is unfortunate, as it may be better to 
use CCR5 antagonists early in the course of HIV-1 infection 
treatment when CCR5-tropic virus predominates. Whether 
patients with D/M virus may derive immunologic beneﬁ  t 
from a CCR5 antagonist without signiﬁ  cant consequence also 
remains to be seen in large studies.
Additional questions that remain to be answered that will 
help guide the use of CCR5 antagonists include whether 
the agents are cross-resistant, synergistic with each other or 
other agents, and, should CXCR4 antagonists be developed, 
whether combination X4/R5 inhibitor therapy would have 
merit. Clearly the addition of another distinct antiretroviral 
class should be met with celebration, particularly since it is 
only 10 years after target identiﬁ  cation. However further 
experience and study are needed to clearly deﬁ  ne the risks, 
beneﬁ  ts, and roles that CCR5 antagonists will have in the 
care of HIV-infected patients.
References
Anderson J, Akkina R. 2007. Complete knockdown of CCR5 by lentiviral 
vector-expressed siRNAs and protection of transgenic macrophages 
against HIV-1 infection. Gene Ther, 14:1287–97.
Baba M, Nishimura O, Kanzaki N, et al. 1999. A small-molecule, nonpeptide 
CCR5 antagonist with highly potent and selective anti-HIV-1 activity. 
Proc Natl Acad Sci USA, 96:5698–703.
Baba M, Takashima K, Miyake H, et al. 2005. TAK-652 inhibits CCR5-
mediated human immunodeﬁ  ciency virus type 1 infection in vitro 
and has favorable pharmacokinetics in humans. Antimicrob Agents 
Chemother, 49:4584–91.
Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple 
combination therapy in antiretroviral-naive HIV-1-1-1 infected adults. 
2001. AIDS, 15:1369–77.
Blanpain C, Migeotte I, Lee B, et al. 1999. CCR5 binds multiple 
CC-chemokines: MCP-3 acts as a natural antagonist. Blood, 
94:1899–905.
Brumme ZL, Goodrich J, Mayer HB, et al. 2005. Molecular and clinical 
epidemiology of CXCR4-using HIV-1 in a large population of antiret-
roviral-naïve individuals. J Infect Dis, 192:466–74.
Chan DC, Fass D, Berger JM, et al. 1997. Core structure of gp41 from the 
HIV envelope glycoprotein. Cell, 89:263–73.
Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell, 93:681–4.
Coakley E, Petropoulos CJ, Whitcomb JM. 2005. Assessing chemokine 
co-receptor usage in HIV. Curr Opin Infect Dis, 18:9–15.
Cocchi F, DeVico AL, Garzino-Demo A, et al. 1995. Identiﬁ  cation of 
RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive 
factors produced by CD8+ T cells. Science, 270:1811–15.
Connor RI, Sheridan KE, Ceradini D, et al. 1997. Change in coreceptor 
use correlates with disease progression in HIV-1 infected individuals. 
J Exp Med, 185:621–8.
Cooper D, Gatell J, Rockstroh J, et al. 2007. Results from BENCHMRK-1, 
a phase III study evaluating the efﬁ  cacy and safety of MK-0518, a novel 
HIV-1integrase inhibitor, in patients with triple-class resistant virus. 
Program and abstracts of the 14th Conference on Retroviruses and 
Opportunistic Infections, Los Angeles, CA, Abstract 105aLB.
Crabb C. 2006. GlaxoSmithKline ends aplaviroc trials. AIDS, 20:641.Therapeutics and Clinical Risk Management 2008:4(2) 483
CCR5 antagonists of HIV-1 infection
Daar ES, Kesler KL, Petropoulos CJ, et al. 2007. Hemophilia Growth and 
Development Study. Baseline HIV type 1 coreceptor tropism predicts 
disease progression. Clin Infect Dis, 45:643–9.
Dalgleish AG, Beverley PC, Clapham PR, et al. 1984. The CD4 (T4) anti-
gen is an essential component of the receptor for the AIDS retrovirus. 
Nature, 312:763–7.
Dean M, Carrington M, Winkler C, et al. 1996. Genetic restriction of HIV-1 
infection and progression to AIDS by a deletion allele of the CKR5 
structural gene: Hemophilia Growth and Development Study, Multi-
center AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San 
Francisco City Cohort, ALIVE Study. Science, 273:1856–62.
Deeks SG. 2006. Challenges of developing R5 inhibitors in antiretroviral 
naive HIV-infected patients. Lancet, 367:711–3.
Dorr P, Westby M, Dobbs S, et al. 2005. Maraviroc (UK-427,857), a potent, 
orally bioavailable, and selective small-molecule inhibitor of chemokine 
receptor CCR5 with broad-spectrum anti-human immunodeﬁ  ciency 
virus type 1 activity. Antimicrob Agents Chemother, 49:4721–32.
Dragic T, Litwin V, Allaway GP, et al. 1996. HIV-1 entry into CD4+ cells is 
mediated by the chemokine receptor CC-CKR-5. Nature, 381:667–73.
Dragic T, Trkola A, Thompson DA, et al. 2000. A binding pocket for a small 
molecule inhibitor of HIV-1 entry within the transmembrane helices of 
CCR5. Proc Natl Acad Sci USA, 97:5639–44.
Eckert DM, Kim PS. 2001. Mechanisms of viral membrane fusion and its 
inhibition. Annu Rev Biochem, 70:777–810.
Fätkenheuer G, Pozniak AL, Johnson MA, et al. 2005. Efﬁ  cacy of short-
term monotherapy with maraviroc, a new CCR5 antagonist, in patients 
infected with HIV-1. Nat Med, 11:1170–2.
Fischereder M, Luckow B, Hocher B, et al. 2001. CC chemokine receptor 
5 and renal-tranplant survival. Lancet, 357:1758–61.
Galvani AP, Slatkin M. 2003. Evaluating plague and smallpox as historical 
selective pressures for the CCR5-∆32 HIV-resistance allele. Proc Natl 
Acad Sci USA, 100:15276–9.
Glass WG, McDermott DH, Lim JK, et al. 2006. CCR5 deﬁ  ciency increases 
risk of symptomatic West Nile virus infection. J Exp Med, 203:35–40.
Goetz MB, Leduc R, Kostman JR, et al. 2007. Prediction of disease progression 
by HIV coreceptor tropism in persons with untreated chronic HIV infec-
tion. Program and abstracts of the 47th Interscience Conference on Anti-
microbial Agents and Chemotherapy, Chicago, Ill. Abstract H-1027.
Goodrich JM, Saag M, van der Ryst E, et al. 2007. 48-week safety and 
efﬁ  cacy of maraviroc, a novel ccr5 antagonist, in combination with 
optimized background therapy (OBT) for the treatment of antiretroviral-
experienced patients infected with dual/mixed-tropic HIV-1. Program 
and abstracts of the 45th Annual Infectious Diseases Society of America, 
San Diego, CA, Abstract LB-2.
Greaves W, Landovitz R, Fätkenheuer G, et al. 2006. Late Virologic break-
through in treatment-naive patients on a regimen of combivir + vicrivi-
roc. Program and abstracts of the 13th Conference on Retroviruses and 
Opportunistic Infections, Denver, CO, Abstract 161LB.
Gulick R, Su Z, Flexner C, et al. 2007a. Phase II study of the safety and 
efﬁ  cacy of vicriviroc in HIV-infected treatment-experienced subjects: 
ACTG 5211. J Infect Dis, 196:304–12.
Gulick R, Su Z, Flexner C, et al. for the ACTG 5211 Team. 2007b. ACTG 
5211: phase II study of the safety and efﬁ  cacy of vicriviroc (VCV) in 
HIV-infected treatment-experienced subjects: 48 week results. Pro-
gram and abstracts of the 4th International AIDS Society Conference 
on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 
Abstract TUAB102.
Gulick R, Haas D, Collier A, et al. 2007c. Two-year follow-up of treatment-
experienced patients on vicriviroc (VCV). Program and abstracts 
of the 47th Interscience Conference on Antimicrobial Agents and 
Chemotherapy, Chicago, IL, Abstract H-1030.
Gulick RM, van der Ryst E, Lampiris H, et al. 2007d. Efﬁ  cacy and safety of once-
daily (QD) compared with twice-daily (BID) maraviroc plus optimized 
background therapy (OBT) in treatment-experienced patients infected 
with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 
1 and 2 studies. Program and abstracts of the 4th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention. Abstract WEPEB116LB.
Guo Q, Ho HT, Dicker I, et al. 2003. Biochemical and genetic 
characterizations of a novel human immunodeﬁ  ciency virus type 1 
inhibitor that blocks gp120-CD4 interactions. J Virol, 77:10528–36.
Hammer SM, Saag MS, Schechter M, et al. 2006. International AIDS Society-
USA panel. Treatment for adult HIV-1 infection: 2006 recommendations 
of the International AIDS Society-USA panel. JAMA, 296:827–43.
Hartley O, Gaertner H, Wilken J, et al. 2004. Medicinal chemistry applied to 
a synthetic protein: development of highly potent HIV entry inhibitors. 
Proc Natl Acad Sci USA, 101:16460–5.
Holmberg SD, Hamburger EM, Moorman AC, et al. 2003. Factors associ-
ated with maintenance of long-term plasma human immunodeﬁ  ciency 
virus RNA suppression. Clin Infect Dis, 37:702–7.
Huang Y, Paxton WA, Wolinsky SM, et al. 1996. The role of a mutant 
CCR5 allele in HIV-1 transmission and disease progression. Nat Med, 
2:1240–3.
Jacobson JM, Israel RJ, Lowy I, et al. 2004. Treatment of advanced human 
immunodeﬁ  ciency virus type 1 disease with the viral entry inhibitor 
PRO 542. Antimicrob Agents Chemother, 48:423–9.
Jacobson JM, Thompson M, Saag MS, et al. 2007. Antiretroviral Activity 
and Pharmacodynamics of PRO 140, a CCR5 Monoclonal Antibody, 
in HIV-Infected Individuals. Program and abstracts of the 47th Annual 
Interscience Conference on Antimicrobial Agents and Chemotherapy, 
Chicago, IL, Abstract H-716.
Ji C, Zhang J, Dioszegi M, et al. 2007. CCR5 small-molecule antagonists 
and monoclonal antibodies exert potent synergistic antiviral effects by 
cobinding to the receptor. Mol Pharmacol, 72:18–28.
Jouvenot Y, Perez E, Urnov FD, et al. 2005. Towards Gene Knock Out 
Therapy for AIDS/HIV: Targeted Disruption of CCR5 Using Engi-
neered Zinc Finger Protein Nucleases (ZFNs). Program and abstracts 
of the 45th Annual Interscience Conference on Antimicrobial Agents 
and Chemotherapy, Washington, DC, Abstract H-1084.
Kadow J, Wang HG, Lin PF. 2006. Small-molecule HIV-1 gp120 inhibitors 
to prevent HIV-1 entry: an emerging opportunity for drug development. 
Curr Opin Investig Drugs, 7:721–6.
Koot M, Keet IP, Vos AH, et al. 1993. Prognostic value of HIV-1 syncytium-
inducing phenotype for rate of CD4+ cell depletion and progression to 
AIDS. Ann Intern Med, 118:681–8.
Kuhmann SE, Pugach P, Kunstman KJ, et al. 2004. Genetic and pheno-
typic analyses of human immunodeﬁ  ciency virus type 1 escape from 
a small-molecule CCR5 inhibitor. J Virol, 78:2790-807. Erratum in: 
J Virol, 2005. 78:6706.
Kwong PD, Wyatt R, Robinson J, et al. 1998. Structure of an HIV gp120 
envelope glycoprotein in complex with the CD4 receptor and a neutral-
izing human antibody. Nature, 393:648–59.
Lalezari J, Thompson M, Kumar P, et al. 2005. Antiviral activity and safety 
of 873140, a novel CCR5 antagonist, during short-term monotherapy 
in HIV-infected adults. AIDS, 19:1443–8.
Lalezari J, Lederman M, Yadavalli G, et al. 2006. A phase 1, dose-escalation, 
placebo-controlled study of a fully human monoclonal antibody 
(CCR5mAb004) against CCR5 in patients with CCR5-tropic HIV-1 
infection. Program and abstracts of the 46th Interscience Conference 
on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 
Abstract H-1668.
Lalezari J, Goodrich J, DeJesus E, et al. 2007. MOTIVATE 1. USA and 
Canada. Efﬁ  cacy and safety of maraviroc plus optimized background 
therapy in viremic, ART-experienced patients infected with CCR5-
tropic HIV-1: 24-week results of phase 2b/3 studies. Program and 
abstracts of the 14th Conference on Retroviruses and Opportunistic 
Infections, Los Angeles, CA, Abstract 104bLB.
Lapidot T. 2001. Mechanism of human stem cell migration and repopula-
tion of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-
1/CXCR4 interactions. Ann NY Acad Sci, 938:83–95.
Liu R, Paxton WA, Choe S, et al. 1996. Homozygous defect in HIV-1 core-
ceptor accounts for resistance of some multiply-exposed individuals to 
HIV-1 infection. Cell, 86:367–77.
Luther SA, Cyster JG. 2001. Chemokines as regulators of T cell 
differentiation. Nat Immunol, 2:102–7.Therapeutics and Clinical Risk Management 2008:4(2) 484
Schlecht et al
Maeda K, Yoshimura K, Shibayama S, et al. 2001. Novel low molecular 
weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 
infection through their antagonistic effects on CCR5. J Biol Chem, 
276:35194–200.
Maeda K, Nakata H, Koh Y, et al. 2004. Spirodiketopiperazine-based CCR5 
inhibitor which preserves CC-chemokine/CCR5 interactions and exerts 
potent activity against R5 human immunodeﬁ  ciency virus type 1 in 
vitro. J Virol, 78:8654–62.
Mani M, Kandavelou K, Dy FJ, et al. 2005. Design, engineering, and 
characterization of zinc finger nucleases. Biochem Biophys Res 
Commun, 335:447–57.
Markowitz M, Mohri H, Mehandru S, et al. 2005. Infection with multidrug 
resistant, dual-tropic HIV-1and rapid progression to AIDS: a case report. 
Lancet, 365:1031–8.
Marozsan AJ, Kuhmann SE, Morgan T, et al. 2005. Generation and prop-
erties of a human immunodeﬁ  ciency virus type 1 isolate resistant to 
the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology, 
338:182–99.
Melby T, Despirito M, Demasi R, et al. 2006. HIV-1 coreceptor use in triple-
class treatment-experienced patients: baseline prevalence, correlates, 
and relationship to enfuvirtide response. J Infect Dis, 194:238–46.
Mocroft A, Phillips AN, Friis-Moller N, et al. 2002. Response to antiretroviral 
therapy among patients exposed to three classes of antiretrovirals: 
results from the EuroSIDA Study. Antivir Ther, 1:21–30.
Mori J, Mosley M, Lewis M, et al. 2007. Characterization of maraviroc resis-
tance in patients failing treatment with CCR5-tropic virus in MOTIVATE 
1 and MOTIVATE 2. Program and abstracts of the 16th International HIV 
Drug Resistance Workshop, Barbados, West Indies. Abstract 10.
Mosley M, Smith-Burchnell C, Mori J, et al. 2006. Resistance to the CCR5 
antagonist maraviroc is characterized by dose-response curves that 
display a reduction in maximal inhibition. Program and abstracts of the 
13th Conference on Retroviruses and Opportunistic Infections, Denver, 
Colorado. Abstract 598.
Moyle GJ, Wildﬁ  re A, Mandalia S, et al. 2005. Epidemiology and predic-
tive factors for chemokine receptor use in HIV-1 infection. J Infect 
Dis, 191:866–72.
Moyle GJ, DeJesus E, Bofﬁ   to M, et al. 2007. CXCR4 antagonism: proof 
of activity with AMD11070. Program and abstracts of the 14th Con-
ference on Retroviruses and Opportunistic Infections, Los Angeles, 
CA, Abstract 511.
Murga JD, Franti M, Pevear DC, et al. 2006. Potent antiviral synergy 
between monoclonal antibody and small-molecule CCR5 inhibitors of 
human immunodeﬁ  ciency virus type 1. Antimicrob Agents Chemother, 
50:3289–96.
Nakata H, Maeda K, Miyakawa T, et al. 2005. Potent anti-R5 human 
immunodeﬁ  ciency virus type 1 effects of a CCR5 antagonist, AK602/
ONO4128/GW873140, in a novel human peripheral blood mononuclear 
cell nonobese diabetic-SCID, interleukin-2 receptor gamma-
chain-knocked-out AIDS mouse model. J Virol, 79:2087–96.
Nelson M, Fatkenheuer G, Konourina I, et al. 2007. MOTIVATE 2. Europe, 
Australia and USA. Efﬁ  cacy and safety of maraviroc plus optimized 
background therapy in viremic, ART-experienced patients infected 
with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies. 
Program and abstracts of the 14th Conference on Retroviruses and 
Opportunistic Infections, Los Angeles, CA, Abstract 104aLB.
Oldﬁ  eld V, Keating GM, Plosker G. 2005. Enfuvirtide: a review of its use 
in the management of HIV infection. Drugs, 65:1139–60.
Olson WC, Rabut GE, Nagashima KA, et al. 1999. Differential inhibition 
of human immunodeﬁ  ciency virus type 1 fusion, gp120 binding, and 
CC-chemokine activity by monoclonal antibodies to CCR5. J Virol, 
735:4145–55.
Oppermann M. 2004. Chemokine receptor CCR5: insights into structure, 
function, and regulation. Cell Signal, 16:1201–10.
Palella FJ Jr, Delaney KM, Moorman AC, et al. 1998. Declining morbidity 
and mortality among patients with advanced human immunodeﬁ  ciency 
virus infection. HIV-1 Outpatient Study Investigators. N Engl J Med, 
338:853–60.
Pastore C, Nedellec R, Ramos A, et al. 2006. Human immunodeﬁ  ciency 
virus type 1 coreceptor switching: V1/V2 gain-of-ﬁ  tness mutations 
compensate for V3 loss-of-ﬁ  tness mutations. J Virol, 80:750–8.
Philpott SM. 2003. HIV-1 coreceptor usage, transmission, and disease 
progression. Curr HIV Res, 1:217–27.
Prahalad S. 2006. Negative association between the chemokine receptor 
CCR5-[Delta]32 polymorphism and rheumatoid arthritis: a meta-
analysis. Genes Immun, 7:264–8.
Pugach P, Marozsan AJ, Ketas TJ, et al. 2007. HIV-1 clones resistant to a 
small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 
for entry. Virology, 361:212–28.
Qin XF, An DS, Chen IS, et al. 2003. Inhibiting HIV-1 infection in human 
T cells by lentiviral-mediated delivery of small interfering RNA against 
CCR5. Proc Natl Acad Sci USA, 100:183–8.
Reynes J, Rouzier R, Kanouni T, et al. 2002. SCH C: Safety and antiviral 
effects of a CCR5 receptor antagonist in HIV-1-infected subjects. 
Program and abstracts of the 9th Conference on Retroviruses and 
Opportunistic Infections. Seattle, WA, Abstract 1.
Roschke V, Clark S, Branco L, et al. 2004. Characterization of a panel of 
novel human monoclonal antibodies that speciﬁ  cally antagonize CCR5 
and Block HIV-1 entry. Program and abstracts of the 44th Interscience 
Conference on Antimicrobial Agents and Chemotherapy, Washington, 
D.C., Abstract #2871.
Rufﬁ  ng N, Sullivan N, Sharmeen L, et al. 1998. CCR5 has an expanded 
ligand-binding repertoire and is the primary receptor used by MCP-2 
on activated T cells. Cell Immunol, 189:160–8.
Saag M, Ive P, Heera J, et al. 2007. A multicenter, randomized, 
double-blind, comparative trial of a novel CCR5 antagonist, maraviroc 
versus efavirenz, both in combination with Combivir (zidovudine 
[ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive 
patients infected with R5 HIV 1: Week 48 results of the MERIT 
study. Program and abstracts of the 4th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention, Sydney, Australia, Abstract 
WESS104.
Sabeti PC, Walsh E, Schaffner SF, et al. 2005. The case for selection at 
CCR5-Delta32. PLoS Biol, 3:e378.
Samson M, Libert F, Doranz BJ, et al. 1996. Resistance to HIV-1 infection in 
Caucasian individuals bearing mutant alleles of the CCR-5 chemokine 
receptor gene. Nature, 382:722–5.
Schooley RT, Mellors JW. 2007. No cure yet for HIV-1-1, but therapeutic 
research presses on. J Infect Dis, 195:770–2.
Schurmann D, Fätkenheuer G, Reynes J, et al. 2007. Antiviral activity, phar-
macokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 
14-day monotherapy in HIV-infected adults. AIDS, 21:1293–9.
Shet A, Berry L, Mohri H, et al. 2006. Tracking the prevalence of transmitted 
antiretroviral drug-resistant HIV-1-1: a decade of experience. J Acquir 
Immune Deﬁ  c Syndr, 41:439–46.
Signoret N, Hewlett L, Wavre S, et al. 2005. Agonist-induced endocytosis 
of CC chemokine receptor 5 is clathrin dependent. Mol Biol Cell, 
16:902–17.
Simmons G, Clapham PR, Picard L, et al. 1997. Potent inhibition of HIV-1 
infectivity in macrophages and lymphocytes by a novel CCR5 antago-
nist. Science, 276:276–9.
Starr-Spires LD, Collman RG. 2002. HIV-1 entry and entry inhibitors as 
therapeutic agents. Clin Lab Med, 22:681–701.
Steigbigel R, Kumar P, Eron J, et al. 2007. Results from BENCHMRK-2, a 
phase III study evaluating the efﬁ  cacy and safety of MK-0518, a novel 
HIV-1integrase inhibitor, in patients with triple-class resistant virus. 
Program and abstracts of the 14th Conference on Retroviruses and 
Opportunistic Infections, Los Angeles, CA, Abstract 105bLB.
Stephens JC, Reich DE, Goldstein DB, et al. 1998. Dating the origin of the 
CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. 
Am J Hum Genet, 62:1507–15.
Strizki JM, Xu S, Wagner NE, et al. 2001. SCH-C (SCH 351125), an orally 
bioavailable, small molecule antagonist of the chemokine receptor 
CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. 
Proc Natl Acad Sci USA, 98:12718–23.Therapeutics and Clinical Risk Management 2008:4(2) 485
CCR5 antagonists of HIV-1 infection
Strizki JM, Tremblay C, Xu S, et al. 2005. Discovery and characterization 
of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity 
against human immunodeﬁ  ciency virus type 1. Antimicrob Agents 
Chemother, 49:4911–9.
Takashima K, Miyake H, Kanzaki N, et al. 2005. Highly potent inhibition 
of human immunodeﬁ  ciency virus type 1 replication by TAK-220, an 
orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents 
Chemother, 49:3474–82.
Thio CL, Astemborski J, Bashirova A, et al. 2007. Genetic protection against 
hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 
contributes to viral persistence. J Virol, 81:441–5.
Tsamis F, Gavrilov S, Kajumo F, et al. 2003. Analysis of the mechanism 
by which the small-molecule CCR5 antagonists SCH-351125 and 
SCH-350581 inhibit human immunodeﬁ  ciency virus type 1 entry. 
J Virol, 77:5201–8.
Tsibris AMN, Gulick RM, Su Z, et al. 2007. In vivo emergence of HIV-1 
resistance to the CCR5 antagonist vicriviroc: ﬁ  ndings from ACTG 
A5211. Program and abstracts of the 16th International HIV Drug 
Resistance Workshop, Barbados, West Indies, Abstract 13.
Unutmaz D, KewalRamani VN, Littman DR. 1998. G protein-coupled recep-
tors in HIV and SIV entry: new perspectives on lentivirus-host interac-
tions an on the utility of animal models. Semin Immunol, 10:225–36.
van der Ryst E, Westby M. 2007. Changes in HIV-1 co-receptor tropism for 
patients participating in the maraviroc Motivate 1 and 2 clinical trials. 
Program and abstracts of the 47th Interscience Conference on Antimi-
crobial Agents and Chemotherapy, Chicago, IL, Abstract H–715.
Walensky RP, Paltiel AD, Losina E, et al. 2006. The survival beneﬁ  ts of 
AIDS treatment in the United States. J Infect Dis, 194:11–9.
Westby M, Lewis M, Whitcomb J, et al. 2006. Emergence of CXCR4-using 
human immunodeﬁ  ciency virus type 1 (HIV-1) variants in a minority of 
HIV-1-infected patients following treatment with the CCR5 antagonist 
maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol, 
80:4909–20.
Westby M, Smith-Burchnell C, Mori J, et al. 2007. Reduced maximal 
inhibition in phenotypic susceptibility assays indicates that viral strains 
resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound 
receptor for entry. J Virol, 81:2359–71.
Wilkin TJ, Su Z, Kuritzkes DR, et al. 2007. HIV type 1 chemokine core-
ceptor use among antiretroviral-experienced patients screened for a 
clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. 
J Infect Dis, 44:591–5.
Wong MM, Fish EN. 2003. Chemokines: attractive mediators of the immune 
response. Semin Immunol, 15:5–14.
Wood A, Armour D. 2005. The discovery of the CCR5 receptor antagonist, 
UK-427,857, a new agent for the treatment of HIV infection and AIDS. 
Prog Med Chem, 43:239–71.
Zhao J, Ma L, Wu YL, et al. 1998. Chemokine receptor CCR5 functionally 
couples to inhibitory G proteins and undergoes desensitization. J Cell 
Biochem, 71:36–45.